|Therapeutic Classification||PPI (Proton pump inhibitors)|
|Storage||store in a cool, dry place and avoid direct sunlight|
Rabeprazole 20mg + Domperidone 10mg Salt Information :
Uses of Rabeprazole 20mg + Domperidone 10mg:
Rabeprazole sodium and domperidone uses include various gastric conditions which leads to gastric reflux or other symptoms like heartburn, gastric ulcers, difficulty swallowing, and persistent cough.
Side Effects of Rabeprazole 20mg + Domperidone 10mg:
Increased risk of Clostridium difficile-associated diarrhoea (CDAD) and osteoporosis-related fractures. Headache, rash, pruritus, dizziness, fatigue, cough, back or abdominal pain, arthralgia and myalgia, urticaria, dry mouth, photosensitivity, bullous eruption, fever, angioedema, bronchospasm, somnolence, aggression and vertigo, insomnia, reversible confusional states, depression, agitation, hallucination. Increased liver enzyme, hepatitis, jaundice, hepatic encephalopathy. Rarely, candidiasis, paraesthesia, alopecia, muscular weakness, angina, tachycardia, bradycardia, blurred vision, alopecia, stomatitis, increased sweating, taste disturbances, peripheral oedema, malaise, hyponatraemia, hypomagnesaemia, blood disorders (e.g. agranulocytosis, leucopenia and thrombocytopenia), gynaecomastia, impotence and interstitial nephritis. Potentially Fatal: Anaphylaxis, Stevens-Johnson syndrome and toxic epidermal necrolysis.
Drug Interactions of Rabeprazole 20mg + Domperidone 10mg:
May decrease serum concentration of ketoconazole, itraconazole and clopidogrel. Increased risk of hypomagnesaemia w/ diuretics and digoxin. May increase prothrombin time and INR of warfarin. May increase plasma concentration of saquinavir and methotrexate. Decreased serum levels w/ sucralfate. Potentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine and atazanavir.
Contraindications of Rabeprazole 20mg + Domperidone 10mg:
Concomitant use w/ rilpivirine and atazanavir.
Mechanism of Action of Rabeprazole 20mg + Domperidone 10mg:
Rabeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase at the secretory surface of the gastric parietal cell. Onset: W/in 1 hr. Duration: 24 hr. Absorption: Rapidly absorbed. Oral bioavailability: Approx 52%. Time to peak plasma concentration: Approx 3.5 hr. Distribution: Plasma protein binding: Approx 97%. Metabolism: Extensive hepatic metabolism mainly by CYP2C19 and CYP3A4 isoenzymes. Excretion: Mainly via urine (approx 90%), the remainder via faeces. Plasma half-life: Approx 1-2 hr.
Special Precautions for Rabeprazole 20mg + Domperidone 10mg:
Gastric malignancy should be ruled out. Severe hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor Mg levels prior to initiation and periodically during prolonged use.